Benchmark’s first quarter was marked by a negative market reaction, reflecting concerns over revenue softness and ongoing macroeconomic uncertainty. Management attributed the year-over-year decline in sales to demand challenges in several key end markets and highlighted the impact of evolving global tariffs, which disrupted customer decision cycles. CEO Jeff Benck specifically pointed to “tariff related market uncertainty” as a factor lengthening customer purchasing decisions and delaying new program ramps, while noting strength in the semiconductor capital equipment and defense segments helped offset some of the weakness.
Is now the time to buy BHE? Find out in our full research report (it’s free).
Benchmark (BHE) Q1 CY2025 Highlights:
- Revenue: $631.8 million vs analyst estimates of $640 million (6.5% year-on-year decline, 1.3% miss)
- Adjusted EPS: $0.52 vs analyst estimates of $0.50 (4% beat)
- Revenue Guidance for Q2 CY2025 is $640 million at the midpoint, below analyst estimates of $668.8 million
- Adjusted EPS guidance for Q2 CY2025 is $0.55 at the midpoint, below analyst estimates of $0.56
- Operating Margin: 3.7%, in line with the same quarter last year
- Market Capitalization: $1.39 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Benchmark’s Q1 Earnings Call
- Jim Ricchiuti (Needham & Company) asked if customer shipment pull-ins and pauses due to tariff uncertainty would have a net positive or negative effect in Q2. CEO Jeff Benck responded that the effects are largely offsetting, resulting in a neutral near-term impact but increased unpredictability.
- Steven Fox (Fox Advisors) questioned what segments, aside from defense and semiconductor capital equipment, would drive growth in the second half. Benck pointed to medical and computing as areas with improving outlooks, but noted recovery timing is still uncertain.
- Jaeson Schmidt (Lake Street) inquired whether the expected rebound in medical will come from channel replenishment or new program launches. Benck explained that both improved channel conditions and new customer wins should contribute to the recovery.
- Anja Soderstrom (Sidoti) asked about capacity utilization in North America and the company’s ability to absorb new business. Benck stated that Benchmark’s U.S. and Mexican facilities have ample space due to recent investments and are well-positioned for potential production shifts.
- Melissa Fairbanks (Raymond James) sought clarity on whether the lengthened customer decision cycles due to macro uncertainty would extend headwinds beyond the next few quarters. Benck acknowledged the possibility, especially for greenfield projects, but indicated competitive takeaways could ramp revenue more quickly.
Catalysts in Upcoming Quarters
Over the coming quarters, the StockStory team will focus on (1) the pace of recovery in medical and computing as inventory levels normalize and new programs launch, (2) the impact of further tariff or regulatory changes on customer demand and supply chain decisions, and (3) continued momentum in semiconductor capital equipment and defense as offsetting factors to weaker markets. Progress in converting bookings to revenue and the effectiveness of supply chain flexibility will also be critical signposts.
Benchmark currently trades at $38.63, in line with $38.30 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
